MedTrace Logo

The Curative Effect and Security of Interferon Combined Resveratrol on HBeAg Positive Chronic Hepatitis B Patients

NCT03546530 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2020-10-14

No results posted yet for this study

Summary

The purpose of this study is to use Interferon Combined Resveratrol to treat patients with hepatitis B, which may provide a novel therapy target hepatitis B.

Conditions

Interventions

DRUG

Interferon

Interferon

DRUG

Interferon+resveratrol

Interferon+resveratrol

Sponsors & Collaborators

  • The First Hospital of Jilin University

    lead OTHER

Principal Investigators

  • Junqi Niu, PHD · The First Hospital of Jilin University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-01
Primary Completion
2017-01-31
Completion
2017-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03546530 on ClinicalTrials.gov